Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, Safety and Tolerability Study of BMS-986504 in Japanese and Chinese Participants With MTAP-Deleted Advanced Solid Tumors
jRCT2031250413Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of MRTX1719 in Nonhematologic neoplasms, sponsored by Bristol Myers Squibb. Primary endpoint: Maximum plasma concentration (Cmax) of BMS-986504. Started Oct 2025; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250413.